Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Desmopressin (DDAVP) and hemostasis

S Lethagen1

  • 1Department for Coagulation Disorders, University of Lund, Malmö General Hospital, Sweden.

Annals of Hematology
|October 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

European retrospective study of real-life haemophilia treatment.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

The administration of desmopressin by nasal spray: a dose-determination study in patients with mild haemophilia A or von Willebrand's disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

The impact of hepatitis C antibody screening of source plasma donors on hepatitis C virus RNA in factor VIII concentrates.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

HIV-disease progression in Swedish haemophiliacs and the influence of replacement therapy.

Haemophilia : the official journal of the World Federation of Hemophilia·2016

Desmopressin effectively increases blood clotting factors and platelet function, making it a valuable treatment for bleeding disorders. This synthetic vasopressin analogue offers immediate hemostatic benefits with various administration routes.

Area of Science:

  • Pharmacology
  • Hematology
  • Hemostasis

Background:

  • Desmopressin is a synthetic analogue of vasopressin.
  • It lacks the pressor activity of vasopressin.
  • It is a widely used hemostatic agent.

Purpose of the Study:

  • To summarize the hemostatic properties and clinical applications of desmopressin.
  • To outline optimal dosing and administration routes.

Main Methods:

  • Review of desmopressin's pharmacological effects on coagulation factors and platelet function.
  • Analysis of its therapeutic uses in various bleeding conditions.
  • Evaluation of different administration routes and dosages.

Main Results:

Related Experiment Videos

  • Desmopressin causes a two- to sixfold increase in plasma concentrations of factor VIII, von Willebrand factor, and tissue plasminogen activator.
  • It also enhances platelet adhesiveness.
  • Effective in mild hemophilia A, von Willebrand's disease, platelet dysfunction, and reducing surgical blood loss.

    • Conclusions:

    • Desmopressin is an effective hemostatic drug for multiple bleeding disorders.
    • Optimal intravenous dosage is 0.3 mcg/kg.
    • Subcutaneous injection and intranasal spray are viable alternatives, with intranasal spray suitable for home treatment.